Gilead re­ports 'very strong quar­ter' de­spite slip­ping Vek­lury sales

Gilead CEO Dan O’Day un­corked some sol­id Q2 re­sults on Tues­day, tout­ing a surge in Yescar­ta and Trodelvy sales and an uptick in de­mand for HIV med Bik­tarvy. Will sink­ing Covid sales spoil the par­ty?

Vek­lury sales were down 48% last quar­ter, top­ping out at $445 mil­lion. That de­cline was ex­pect­ed, chief com­mer­cial of­fi­cer Jo­han­na Merci­er not­ed, as hos­pi­tal­iza­tion rates fall due to milder cas­es and the up­take of oth­er treat­ments like Pfiz­er’s Paxlovid. Even so, rough­ly 60% of hos­pi­tal­ized Covid pa­tients are treat­ed with Vek­lury, she added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER